SEC Cracks Down on Insider Trading at Drug Firms and Fraud on Crypto Platforms

The Securities and Exchange Commission charged George Demos, a former Vice President of Drug Safety at Acadia Pharmaceuticals, with insider trading on March 7, 2025. The allegation: he bought and sold company stock based on information about a negative FDA decision that hadn't been made public yet. This kind of advance knowledge gives insiders an unfair edge over ordinary investors who don't have access to that information.

Demos's job put him in a position to learn about FDA regulatory decisions before the company announced them publicly. When the FDA rejects or raises concerns about a drug, it can tank a company's stock price within hours. That's why trading on that knowledge before it becomes public is illegal.

A Separate Crypto Platform Case

At the same time, the SEC went after two crypto asset trading platforms—Morocoin Tech Corp. and Berge Blockchain—for allegedly taking $14 million from retail investors. These platforms were accepting money from customers while operating without proper registration or oversight from regulators.

The pattern here is familiar: platforms promise high returns while staying outside the rules that govern traditional investment firms. Individual investors often lack the resources to investigate whether a platform is legitimate, making them vulnerable.

The SEC's Warning System

The SEC maintains something called the PAUSE Program (Public Alerts for Unregistered Soliciting Entities). Think of it as a blacklist. It catalogs companies that falsely claim to be registered, licensed, or operating legally in the United States. Investors and brokers can cross-check suspicious investment offers against this list before handing over money.

As investment fraud has moved online and become more international, this early warning system has become more important, especially in crypto markets where geographic boundaries don't matter as much.

Why This Matters Now

We have seen this pattern before. During the dot-com bubble in 2000, a wave of insider trading cases followed as executives with secret knowledge of failing projects sold their stock before the truth came out. The current boom in AI and biotech investments, combined with the ongoing growth of crypto markets, creates similar opportunities for people with insider information to profit unfairly.

The pharmaceutical insider trading case points to something specific about drug company stocks: they move on FDA news. When regulators make a decision about a drug—approval or rejection—the stock often swings 10, 20, or 30 percent in a single day. Executives in drug safety roles know about these decisions weeks before the public does, which is the core of what makes insider trading possible in this industry.

For crypto platforms, the $14 million case is medium-sized by recent standards. Some enforcement cases have involved smaller amounts, others have touched hundreds of millions in alleged investor losses.

How the Law Works in These Cases

Insider trading cases rest on two legal theories. The first charges negligent or intentional misstatements in securities transactions. The second requires proof of intent—the person knew what they were doing or was recklessly indifferent to the rules—and that's a higher bar for prosecutors to clear.

In pharmaceutical cases, proving insider trading means showing that the regulatory information wasn't yet public—it hadn't been filed in official SEC documents or announced in a press release. The timing of trades compared to internal emails and public announcements becomes the key evidence.

For the crypto platforms, the violations likely involve failing to register as broker-dealers (firms that execute trades for customers) or investment advisers (firms that manage money for clients). Crypto platforms that handle customer funds typically need one or both of these registrations, just as traditional financial firms do.

What Happens Next

These enforcement actions serve a practical purpose: they deter others from breaking the rules. The pharmaceutical case sends a signal to drug company executives that the SEC will prosecute insider trading, which pushes companies to tighten their own policies around when executives can buy and sell stock—typically banning it around major FDA decisions.

The crypto cases extend the SEC's reach into digital asset markets, treating certain crypto platforms as if they were traditional brokers and investment firms. Rather than waiting for new laws, the agency is applying old rules to new technology—a pragmatic approach that avoids legislative delays.

The broader point here is that the SEC is trying to maintain oversight as investment opportunities shift across different technologies and markets. Insider trading and fraud on unregistered platforms are old problems. The tools and platforms change, but the underlying ways people cheat—exploiting information advantages and taking money without proper oversight—stay remarkably consistent. What does change is the SEC's ability to identify and prosecute these activities as they adapt to new platforms and markets.